- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07651761
Patient-Centered Practical Vaccine Talk For Busy Clinicians (PCP-VAX)
Patient-Centered Practical Vaccine Talk for Busy Clinicians (PCP-VAX): An Educational Intervention for Primary Care Providers on Influenza and COVID-19 Vaccine Uptake Among Adult Primary Care Patients
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Low uptake of the COVID-19 and influenza vaccines is a major public health threat. An estimated 234,000 deaths due to COVID-19 could have been prevented between June 2021 and March 2022 through vaccination. Yet, only 20% of US adults are up to date on COVID-19 vaccination, despite widespread vaccine availability, and evidence of vaccine effectiveness at preventing hospitalization or death. Similarly, flu shots prevented an estimated 105,000 hospitalizations and 6,300 deaths during the 2019-2020 season alone, but only 50% of adults received a flu shot in the 2020-2021 influenza season, and these rates have been declining in the years since.
Healthcare provider (HCP) recommendations increase uptake of COVID-19 and influenza vaccines. Interventions that leverage the central role of HCPs in recommending vaccination are a promising means of increasing vaccination coverage. Yet many PCPs are unsure how to communicate effectively with patients who decline vaccination, indicating a need for strategies and training in how to effectively communicate with patients about the COVID-19 and influenza vaccines.
The goal of this study is to assess the effect of an educational intervention for primary care providers (PCPs) on influenza and COVID-19 vaccine uptake among their adult patients through a pragmatic, cluster randomized trial in primary care clinics. Our hypothesis is that training PCPs in evidence-based communication strategies (e.g., making a presumptive recommendation, responding with elements of MI) via the PCP-VAX intervention will be superior to usual care with regards to influenza and COVID-19 vaccine uptake. The trial will be conducted among primary care clinics from 3 health systems in central Massachusetts, including community primary care practices, academic primary care practices, and Federally Qualified Health Centers.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Kimberly A Fisher, MD
- Telefonnummer: (508) 334-1975
- E-mail: kimberly.fisher2@umassmed.edu
Undersøgelse Kontakt Backup
- Navn: Cassie L Saphirak, MA
- Telefonnummer: 508-856-3493
- E-mail: cassandra.saphirak@umassmed.edu
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion criteria for primary care provider participants are as follows:
- Practicing primary care provider at study clinic during the study period
- Licensed independent practitioner (MD, DO, NP, PA), including residents
Exclusion criteria for primary care provider participants are as follows:
- PCPs at participating clinic sites who are members of the investigational team or part of the intervention
- PCP participants who practice at more than one study clinic that are assigned to discordant study arms (e.g., control and intervention) will be excluded at the outset of the study.
Inclusion criteria for patient participants are specified for each of the two co-primary outcomes as follows:
Receipt of the 2026/2027 influenza vaccine, among eligible patients:
- Have a qualifying clinic visit, defined as a clinic visit with a study PCP at one of the study clinics during the 2026/2027 influenza vaccine season*
- Have not received the 2026-2027 influenza vaccine prior to the qualifying clinic visit (patients who receive the influenza vaccine on the day of the qualifying study visit are eligible)
- Adult (age >= 18 years)
Receipt of the 2026/2027 COVID-19 vaccine, among eligible patients:
- Have a qualifying clinic visit, defined as a clinic visit with a study PCP at one of the study clinics during the 2026/2027 COVID-19 vaccine season*
- Have not received the 2026-2027 COVID-19 vaccine prior to the qualifying study visit (patients who receive the COVID-19 vaccine on the day of the qualifying study visit are eligible)
- Have at least one risk factor for developing severe COVID-19 according to the CDC, including age >= 65 years
- Adult (age >= 19 years)
Exclusion criteria for patient participants for both co-primary outcomes are the following:
- Resident of a state that does not share immunization data with the Massachusetts Immunization Information System (MIIS)
For the purposes of this study, the 2026/2027 influenza and COVID-19 vaccine seasons are defined as September 1, 2026, or date the respective vaccine is available (whichever is later) through February 28, 2027. These dates were selected based on the timing of influenza and COVID-19 vaccine administration in prior years according to the Massachusetts immunization for respiratory disease data. This is referred to as the 'study period' elsewhere in the protocol.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Kontrolarm
Sædvanlig pleje
|
|
|
Andet: Intervention Arm
Provider educational intervention.
|
Providers in participating intervention clinics will complete an educational program (PCP-VAX) on strategies for communicating with patients about the influenza and COVID-19 vaccines.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Receipt of 2026/2027 influenza vaccine
Tidsramme: Within one month of the end of the study period
|
Binary variable, yes/no
|
Within one month of the end of the study period
|
|
Receipt of 2026/2027 COVID-19 vaccine
Tidsramme: Within one month of the end of the study period
|
Binary variable, yes/no
|
Within one month of the end of the study period
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
PCP self-efficacy in communicating with patients about vaccination, assessed via 4-questions developed for this study (4-point Likert scale)
Tidsramme: Up to 8-months after enrollment
|
Up to 8-months after enrollment
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Kimberly A Fisher, MD, University of Massachusetts, Worcester
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00001814
- R01MD018611 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med COVID-19
-
PfizerAktiv, ikke rekrutterendeCOVID-19 | Coronavirus sygdom 2019 (COVID-19) | Covid-19-infektion | Vacciner mod covid-19 | SARS-CoV-2-infektion, COVID19 | COVID-19-vaccination | SARS-CoV-2-infektion, COVID-19 | COVID-19 (Coronavirus sygdom 2019) | COVID-19 SARS-CoV-2-infektionForenede Stater
-
PfizerRekrutteringLuftvejssygdomme | COVID-19 | Lungebetændelse | Lungesygdomme | Coronavirussygdom 2019 | Coronavirus sygdom 2019 (COVID-19) | Covid-19-infektion | Øvre luftvejsinfektioner | Luftvejsinfektion | COVID-19 (Coronavirus sygdom 2019) | COVID-19 SARS-CoV-2-infektionBelgien
-
Shanghai Public Health Clinical CenterIkke rekrutterer endnu
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Afsluttet
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RekrutteringTilstand efter COVID-19 | Efter COVID-19 | Post COVID-19 syndrom | Langt COVID-19 syndrom | Post COVID-19 tilstand (PCC)Tyskland
-
Yang I. PachankisAktiv, ikke rekrutterendeCOVID-19 luftvejsinfektion | COVID-19 stresssyndrom | COVID-19-vaccinebivirkning | COVID-19-associeret tromboembolisme | COVID-19 Post-Intensive Care Syndrome | COVID-19-associeret slagtilfældeKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico og andre samarbejdspartnereAfsluttetPostakutte følgesygdomme af COVID-19 | Tilstand efter COVID-19 | Langtids-COVID | Kronisk COVID-19 syndromItalien
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRekrutteringTræthed | Post-COVID-19 syndrom | Tilstand efter COVID-19 | Post-COVID syndrom | Lang COVID-19 | Langtids-COVID | Post-COVID tilstandCanada
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Aktiv, ikke rekrutterendeCovid-19 testadfærdForenede Stater
-
RSUP PersahabatanAfsluttetPost COVID-19 syndrom | Langt COVID-19 syndrom | Post COVID-syndrom Long CovidIndonesien
Kliniske forsøg med Provider communication training
-
Jacobs University Bremen gGmbHGoethe University; University Hospital Ulm; Techniker Krankenkasse; German... og andre samarbejdspartnereAfsluttetGraviditetsrelateretTyskland
-
The University of Texas Health Science Center,...The Institute for Rehabilitaion and Research FoundationAfsluttetTraumatisk hjerneskadeForenede Stater
-
University of ChicagoNational Institute on Aging (NIA)AfsluttetDemens | Meddelelse | Alzheimers sygdom | Primær progressiv afasi | AfasiForenede Stater
-
Jordan University of Science and TechnologyAfsluttetAutismespektrumforstyrrelseJordan
-
University of ChicagoNational Institute on Aging (NIA)AfsluttetPrimær progressiv afasiForenede Stater
-
University of ChicagoNational Institute on Aging (NIA); Western University, CanadaRekruttering
-
Bao YanRekruttering
-
McMaster UniversityHealth CanadaRekrutteringMeddelelse | Palliativ pleje | Uddannelse af primære klinikereCanada
-
Gazi UniversityAfsluttetMotionstræningTyrkiet (Türkiye)
-
Hasselt UniversityTel Aviv University; Sheba Medical Center; Centre Hospitalier Universitaire... og andre samarbejdspartnereAfsluttet